ME Therapeutics Holdings Inc. METXF
OTC PK
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.42% | -40.72% | |||
| Depreciation & Amortization | -3.40% | 8.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.77% | -11.88% | |||
| Operating Income | -31.77% | 11.88% | |||
| Income Before Tax | -37.77% | 17.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.77% | 17.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.77% | 17.09% | |||
| EBIT | -31.77% | 11.88% | |||
| EBITDA | -33.43% | 12.77% | |||
| EPS Basic | -37.14% | 17.65% | |||
| Normalized Basic EPS | -36.36% | 16.98% | |||
| EPS Diluted | -31.51% | 14.12% | |||
| Normalized Diluted EPS | -36.36% | 16.98% | |||
| Average Basic Shares Outstanding | 0.00% | 0.87% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||